Gilead Sciences (NASDAQ:GILD) Earns Neutral Rating from Cantor Fitzgerald

Gilead Sciences (NASDAQ:GILD - Get Free Report)'s stock had its "neutral" rating reissued by research analysts at Cantor Fitzgerald in a research report issued on Monday, Benzinga reports. They presently have a $70.00 price objective on the biopharmaceutical company's stock. Cantor Fitzgerald's price objective indicates a potential downside of 15.82% from the company's previous close.

A number of other brokerages have also recently weighed in on GILD. Evercore ISI upgraded shares of Gilead Sciences to a "strong-buy" rating in a research note on Friday, August 9th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Raymond James raised shares of Gilead Sciences from a "market perform" rating to an "outperform" rating and set a $93.00 target price on the stock in a research report on Monday, July 8th. Royal Bank of Canada boosted their target price on shares of Gilead Sciences from $72.00 to $74.00 and gave the stock a "sector perform" rating in a research report on Wednesday, September 4th. Finally, Robert W. Baird reaffirmed a "neutral" rating and set a $80.00 target price on shares of Gilead Sciences in a research report on Thursday, June 20th. Twelve equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $82.06.

Gilead Sciences Stock Up 0.4 %

NASDAQ GILD traded up $0.35 during trading on Monday, reaching $83.16. The company's stock had a trading volume of 7,844,117 shares, compared to its average volume of 7,172,206. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. The stock has a market capitalization of $103.53 billion, a PE ratio of 230.14, a PEG ratio of 2.80 and a beta of 0.18. The business has a 50-day moving average price of $75.48 and a 200-day moving average price of $70.84. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $87.86.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts' consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The business had revenue of $6.95 billion during the quarter, compared to analysts' expectations of $6.64 billion. On average, research analysts forecast that Gilead Sciences will post 3.78 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now owns 96,380 shares in the company, valued at approximately $6,614,559.40. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the company's stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares in the company, valued at approximately $8,506,146.42. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now owns 96,380 shares in the company, valued at $6,614,559.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 36,847 shares of company stock worth $3,002,940. Corporate insiders own 0.16% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. CarsonAllaria Wealth Management Ltd. lifted its position in Gilead Sciences by 198.3% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 238 shares during the period. Sachetta LLC acquired a new position in Gilead Sciences during the 4th quarter valued at about $30,000. Palisade Asset Management LLC bought a new stake in shares of Gilead Sciences in the 1st quarter valued at about $29,000. Frank Rimerman Advisors LLC bought a new stake in shares of Gilead Sciences in the 4th quarter valued at about $36,000. Finally, Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $33,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.